LIA
CRSP icon

Limestone Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Limestone Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,100
Closed -$297K – 567
2025
Q2 		$297K Buy
+6,100
New +$236K 0.03% 331

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Limestone Investment Advisors's CRSP Position: Q3 2025 in Review

Limestone Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 6,100 shares — an estimated $297K sold.

Limestone Investment Advisors first reported a position in CRSP in Q2 2025 and held it in 1 quarter. The position peaked at $297K in Q2 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Limestone Investment Advisors reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Limestone Investment Advisors sold 6,100 CRISPR Therapeutics shares in Q3 2025, an estimated $297K.
  • Limestone Investment Advisors first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 1 quarter.
  • Limestone Investment Advisors's CRISPR Therapeutics position peaked at $297K in Q2 2025.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Limestone Investment Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.